Yang Li-Yuan, Yang Li-Peng, Zhu Biao
Department of Intensive Care Unit, Fudan University Shanghai cancer center, Shanghai 200032, China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Oncotarget. 2017 Jul 19;8(43):74287-74298. doi: 10.18632/oncotarget.19396. eCollection 2017 Sep 26.
To investigate the clinicopathological characteristics and to determine whether there is a differential effect of race and examine survival outcomes according to race, 18,295 breast invasive lobular carcinoma (ILC) patients were identified in the Surveillance, Epidemiology, and End Result (SEER) database, which includes White patients (n=15,936), Black patients (n=1,451) and patients of other races (including American Indians/Alaskan Natives and Asian/Pacific Islanders) (n=908). The Black ILC patients presented a higher rate of advanced histological grades and American Joint Committee on Cancer (AJCC) stages, a higher rate of lymph node (LN) involvement and a lower rate of progesterone receptors (PR)-positivity than the White patients and other races. The five-year overall survival (OS) and five-year breast cancer specific survival (BCSS) were worst in the Black patients among these patients (85.5%, 76.0% and 87.7%, P<0.01; 91.1%, 84.4% and 91.6%, P<0.01). Multivariate regression analyses were performed to determine the risk hazards ratios (HR) of death for patients of the White, Black and other races. Among these patients, the Black patients had the worst survival outcomes in five-year OS and BCSS outcomes (HR=1.35, 95% confidence interval (CI) :1.20-1.51, P<0.01; HR=1.39, 95%CI:1.21-1.61, P<0.01, respectively). After a 1:1:1 matching of the three groups, the Black patients still presented worse survival outcomes in BCSS compared to White patients (HR=1.88, 95%CI: 1.14-3.10, P=0.013), however, there was no difference in OS (HR=1.35, 95%CI: 0.93-1.96, P=0.111). Difference in outcomes may partially explained by difference in histological grades, AJCC stage, LN and PR status among the three groups. In conclusion, this study revealed that the Black patients had worse five-year OS and BCSS than White and other race patients.
为了研究临床病理特征,并确定种族是否存在差异影响以及根据种族检查生存结果,在监测、流行病学和最终结果(SEER)数据库中识别出18295例乳腺浸润性小叶癌(ILC)患者,其中包括白人患者(n = 15936)、黑人患者(n = 1451)和其他种族患者(包括美洲印第安人/阿拉斯加原住民和亚洲/太平洋岛民)(n = 908)。与白人患者和其他种族相比,黑人ILC患者具有更高的高级组织学分级和美国癌症联合委员会(AJCC)分期率、更高的淋巴结(LN)受累率和更低的孕激素受体(PR)阳性率。在这些患者中,黑人患者的五年总生存率(OS)和五年乳腺癌特异性生存率(BCSS)最差(分别为85.5%、76.0%和87.7%,P<0.01;91.1%、84.4%和91.6%,P<0.01)。进行多变量回归分析以确定白人、黑人和其他种族患者的死亡风险比(HR)。在这些患者中,黑人患者在五年OS和BCSS结果中的生存结果最差(HR = 1.35,95%置信区间(CI):1.20 - 1.51,P<0.01;HR = 1.39,95%CI:1.21 - 1.61,P<0.01)。在三组进行1:1:1匹配后,与白人患者相比,黑人患者在BCSS方面的生存结果仍然较差(HR = 1.88,95%CI:1.14 - 3.10,P = 0.013),然而,在OS方面没有差异(HR = 1.35,95%CI:0.93 - 1.96,P = 0.111)。结果的差异可能部分由三组之间组织学分级、AJCC分期、LN和PR状态的差异所解释。总之,本研究表明黑人患者的五年OS和BCSS比白人和其他种族患者更差。